Summation
- This acquisition would complement Stryker’s existing presence in France and across Europe as well as its global joint replacement portfolio, allowing Stryker to serve a wider range of patients.
- In accordance with French law, the execution of any binding agreement would occur after the works council information-consultation process has been completed.
- The proposed acquisition is expected to close during the first quarter of 2024, subject to customary closing conditions, including regulatory approvals.
Stryker (NYSE: SYK), one of the world’s leading medical technology companies, announced today that it has executed a binding offer to Menix to acquire SERF SAS, a France-based joint replacement company.
With a legacy of over 50 years, SERF SAS is recognized by healthcare professionals worldwide for its innovations in hip implants, including the invention of the original Dual Mobility Cup. This acquisition would complement Stryker’s existing presence in France and across Europe as well as its global joint replacement portfolio, allowing Stryker to serve a wider range of patients.
In accordance with French law, the execution of any binding agreement would occur after the works council information-consultation process has been completed. The proposed acquisition is expected to close during the first quarter of 2024, subject to customary closing conditions, including regulatory approvals.
